235 related articles for article (PubMed ID: 16720366)
1. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
[TBL] [Abstract][Full Text] [Related]
2. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
Ramezani A; Ma XZ; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA.
Nazari R; Ma XZ; Joshi S
J Gen Virol; 2008 Sep; 89(Pt 9):2252-2261. PubMed ID: 18753234
[TBL] [Abstract][Full Text] [Related]
4. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
Ramezani A; Joshi S
Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
Ramezani A; Ding SF; Joshi S
Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
[TBL] [Abstract][Full Text] [Related]
7. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
Sun LQ; Wang L; Gerlach WL; Symonds G
Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
[TBL] [Abstract][Full Text] [Related]
8. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
Zhou C; Bahner I; Rossi JJ; Kohn DB
Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA.
Lo KM; Biasolo MA; Dehni G; Palú G; Haseltine WA
Virology; 1992 Sep; 190(1):176-83. PubMed ID: 1529527
[TBL] [Abstract][Full Text] [Related]
10. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
[TBL] [Abstract][Full Text] [Related]
12. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells.
Hormes R; Homann M; Oelze I; Marschall P; Tabler M; Eckstein F; Sczakiel G
Nucleic Acids Res; 1997 Feb; 25(4):769-75. PubMed ID: 9016627
[TBL] [Abstract][Full Text] [Related]
13. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
Medina MF; Joshi S
Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 replication by RNA targeted against the LTR region.
Puerta-Fernández E; Barroso-del Jesus A; Romero-López C; Tapia N; Martínez MA; Berzal-Herranz A
AIDS; 2005 Jun; 19(9):863-70. PubMed ID: 15905666
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
[TBL] [Abstract][Full Text] [Related]
16. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.
Gervaix A; Li X; Kraus G; Wong-Staal F
J Virol; 1997 Apr; 71(4):3048-53. PubMed ID: 9060665
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.
Morris KV; Rossi JJ
Curr HIV Res; 2004 Apr; 2(2):185-91. PubMed ID: 15078182
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
[TBL] [Abstract][Full Text] [Related]
19. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
Tabler M; Homann M; Tzortzakaki S; Sczakiel G
Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs.
Gu S; Ji J; Kim JD; Yee JK; Rossi JJ
Oligonucleotides; 2006; 16(4):287-95. PubMed ID: 17155905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
